Literature DB >> 33775123

Mechanisms Underlying Vascular Endothelial Growth Factor Receptor Inhibition-Induced Hypertension: The HYPAZ Trial.

Kaisa M Mäki-Petäjä1, Adam McGeoch1, Lucy L Yang1, Annette Hubsch1, Carmel M McEniery1, Paul A R Meyer1,2, Fraz Mir1, Parag Gajendragadkar1, Nicola Ramenatte3, Gayathri Anandappa4, Sara Santos Franco5, Simon J Bond3, Carola-Bibiane Schönlieb6, Yoeri Boink7,8, Christoph Brune7, Ian B Wilkinson1,3, Duncan I Jodrell4,3, Joseph Cheriyan1,3.   

Abstract

[Figure: see text].

Entities:  

Keywords:  acetylcholine; cardiovascular disease; hypertension; microvascular rarefaction; pazopanib

Mesh：

Substances：

Year:  2021        PMID： 33775123      PMCID： PMC7610566          DOI： 10.1161/HYPERTENSIONAHA.120.16454

Source DB:  PubMed          Journal:  Hypertension        ISSN： 0194-911X            Impact factor:   10.190


  26 in total

1.  Ridge-based vessel segmentation in color images of the retina.

Authors:  Joes Staal; Michael D Abràmoff; Meindert Niemeijer; Max A Viergever; Bram van Ginneken
Journal:  IEEE Trans Med Imaging       Date:  2004-04       Impact factor: 10.048

2.  Reproducibility of pulse wave velocity and augmentation index measured by pulse wave analysis.

Authors:  I B Wilkinson; S A Fuchs; I M Jansen; J C Spratt; G D Murray; J R Cockcroft; D J Webb
Journal:  J Hypertens       Date:  1998-12       Impact factor: 4.844

Review 3.  Mechanisms of VEGF (Vascular Endothelial Growth Factor) Inhibitor-Associated Hypertension and Vascular Disease.

Authors:  Arvind K Pandey; Eric K Singhi; Juan Pablo Arroyo; Talat Alp Ikizler; Edward R Gould; Jonathan Brown; Joshua A Beckman; David G Harrison; Javid Moslehi
Journal:  Hypertension       Date:  2017-12-26       Impact factor: 10.190

Review 4.  The circulation of the human limbus.

Authors:  P A Meyer
Journal:  Eye (Lond)       Date:  1989       Impact factor: 3.775

5.  Re-orchestration of blood flow by micro-circulations.

Authors:  P A R Meyer
Journal:  Eye (Lond)       Date:  2018-01-19       Impact factor: 3.775

6.  Large artery stiffness and hypertension after antiangiogenic drugs: influence on cancer progression.

Authors:  Maureen Alivon; Julie Giroux; Marie Briet; François Goldwasser; Stéphane Laurent; Pierre Boutouyrie
Journal:  J Hypertens       Date:  2015-06       Impact factor: 4.844

Review 7.  Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma.

Authors:  Sidney V Keisner; Sachin R Shah
Journal:  Drugs       Date:  2011-03-05       Impact factor: 9.546

8.  Pazopanib.

Authors:  Ronald M Bukowski; Uma Yasothan; Peter Kirkpatrick
Journal:  Nat Rev Drug Discov       Date:  2010-01       Impact factor: 84.694

9.  Incidence and risk of hypertension with pazopanib in patients with cancer: a meta-analysis.

Authors:  Wei-Xiang Qi; Feng Lin; Yuan-Jue Sun; Li-Na Tang; Ai-Na He; Yang Yao; Zan Shen
Journal:  Cancer Chemother Pharmacol       Date:  2012-11-21       Impact factor: 3.333

Review 10.  Tyrosine Kinase Inhibitor-Induced Hypertension.

Authors:  Megha Agarwal; Nidhi Thareja; Melody Benjamin; Andre Akhondi; George D Mitchell
Journal:  Curr Oncol Rep       Date:  2018-06-21       Impact factor: 5.075
View more
  1 in total

Review 1.  Hypertension in Cancer Survivors: A Review of the Literature and Suggested Approach to Diagnosis and Treatment.

Authors:  David Chuquin; Antonio Abbate; Wendy Bottinor
Journal:  J Cardiovasc Pharmacol       Date:  2022-10-01       Impact factor: 3.271
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.